FDA to Review Easing Restrictions on Peptides

Summary

The FDA will hold a summer meeting to consider easing restrictions on certain peptide injections, encouraged by RFK Jr. and the Trump administration. Bloomberg Businessweek senior reporter Amanda Mull explains how the current black market for peptides is estimated at $1-2 billion and could grow significantly if more peptides are approved for compounding. The discussion covers how GLP-1 drug success has normalized self-injection, lowering barriers for home-injected treatments, and notes that compound pharmacies could pose a disruptive threat to traditional pharmaceutical companies.

• FDA to review easing restrictions on peptide injections after encouragement from RFK Jr.
• Black market for peptides currently estimated at $1-2 billion in the US.
• If 14 peptides referenced by RFK Jr. are approved for compounding, the market could double or triple.
• GLP-1 drugs (like Ozempic) are peptide-based and have proven safe and highly effective, fueling interest in other peptides.
• Increased comfort with self-injection, driven by GLP-1s and med spa treatments, has reduced a key adoption barrier.
• Some drug suppliers are already moving into the space early, anticipating lax enforcement.
• Compounding pharmacies could undercut patented drugs, posing a potential disruption for major pharma companies.